Mesenchymal Stromal Cells Based Therapy in Systemic Sclerosis: Rational and Challenges

Area of Science:

• Immunology
• Rheumatology
• Cellular Biology

Background:

• Systemic Sclerosis (SSc) is a rare, chronic autoimmune disease with significant morbidity and mortality, primarily due to fibrosis, vascular damage, and immune system activation.
• The diffuse cutaneous scleroderma subtype presents rapid progression and poor prognosis, with lung failure being the leading cause of death.
• Current treatments focus on modulating fibrotic and inflammatory pathways, but overall patient survival remains suboptimal compared to other inflammatory diseases.

Purpose of the Study:

• To explore the potential of cellular therapy, specifically mesenchymal stromal cells (MSCs), as a novel treatment for Systemic Sclerosis.
• To highlight the immunomodulatory, anti-inflammatory, and antifibrotic properties of MSCs relevant to SSc pathophysiology.
• To review the current status and challenges of MSC-based therapies in autoimmune diseases and SSc management.

Main Methods:

• Review of existing literature on Systemic Sclerosis pathophysiology and treatment modalities.
• Analysis of the therapeutic properties of mesenchymal stromal cells (MSCs), including their mechanisms of action.
• Examination of clinical trial data and regulatory considerations for MSCs as Advanced Therapy Medicinal Products (ATMPs).

Main Results:

• Mesenchymal stromal cells (MSCs) exhibit potent anti-inflammatory, antiproliferative, antifibrotic, and immunomodulatory effects through the secretion of bioactive molecules.
• MSCs can adapt their function based on the inflammatory microenvironment, making them suitable for complex autoimmune conditions like SSc.
• While MSCs have shown promise in various autoimmune diseases, few randomized clinical trials specifically for SSc have been published, and their regulatory production is complex.

Conclusions:

• Mesenchymal stromal cells (MSCs) represent a promising therapeutic avenue for Systemic Sclerosis, addressing key pathological features such as fibrosis and inflammation.
• Further randomized clinical trials are necessary to establish the efficacy and safety of MSCs and their derived products in SSc management.
• The complex regulatory landscape for ATMPs and the need for combination therapies require careful consideration for the clinical implementation of MSCs in SSc treatment.